GERMANTOWN, Md., May 16,
2019 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a
biopharmaceutical company developing novel treatments for nervous
system diseases, today announced the expansion of their
intellectual property portfolio with the recent issuance of a newly
published patent. U.S. Patent No. 10,286,010, entitled "Methods of
Treating Neurodegenerative Conditions" was issued on May 14, 2019, by the United States Patent and
Trademark Office (USPTO). The patent covers the use of transplanted
human neural stem cells for the treatment of neurodegeneration
resulting from disease and injury.
"We are very pleased to have been awarded this patent," said Dr.
Kenneth Carter, Ph.D, Executive
Chairman of Neuralstem. "It provides Neuralstem with broad
protection for the use of our neural stem cells in the treatment of
diseases such as stroke, traumatic brain injury, spinal cord
injury, and ALS, and extends the scope and lifespan of our neural
stem cell IP portfolio."
About Neuralstem
Neuralstem is a clinical-stage
biopharmaceutical company developing novel treatments for nervous
system diseases of high unmet medical need. The Company has two
lead development candidates:
- NSI-566 is a stem cell therapy being tested in clinical trials
for treatment of paralysis due to ischemic stroke, amyotrophic
lateral sclerosis (ALS), and chronic spinal cord injury (cSCI).
Results from these trials have indicated that NSI-566 is safe and
provided preliminary evidence of clinical benefit across all three
indications.
- NSI-189 is a small molecule in clinical development for major
depressive disorder and in preclinical development for Angelman
syndrome, irradiation-induced cognitive impairment, diabetic
neuropathy, and stroke.
In February, 2019, the Company announced the initiation of
efforts to identify preclinical and clinical stage assets that
could be acquired and developed to expand its current pipeline of
therapeutic products.
Cautionary Statement Regarding Forward Looking
Information
This news release contains "forward-looking
statements" made pursuant to the "safe harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Such
forwardlooking statements relate to future, not past, events and
may often be identified by words such as "expect," "anticipate,"
"intend," "plan," "believe," "seek" or "will." Forwardlooking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem's
periodic reports, including its Annual Report on Form 10-K for the
year ended December 31, 2018, filed
with the Securities and Exchange Commission (SEC), and in other
reports filed with the SEC. We do not assume any obligation to
update any forward-looking statements.
Investor Contact:
Sunflower Life Sciences
josh@sunflowerlifesciences.com
View original
content:http://www.prnewswire.com/news-releases/neuralstem-announces-issuance-of-new-patent-covering-broad-therapeutic-use-of-neural-stem-cells-300850370.html
SOURCE Neuralstem, Inc.
